Inflammatory nasal polyp. Nasal polyp, unspecified
Conditions
Interventions
Intervention 1: First intervention group: Patients in the first group are treated with beclomethasone nasal spray produced by Raha pharmaceutical company 50 µg/dose 2 puff in each nose per day for 2 m
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Patients from the age of 18-55 years who suffer from inflammatory nasal polyps Obtaining written consent to participate in the study
Exclusion criteria
Exclusion criteria: Previous sensitivity to beclomethasone Pregnancy or breast-feeding Severe kidney, heart, liver, neurologic, collagen-vascular, malignancy disease, untreated bacterial or fungal infection History of trauma and facial fractures Use of systemic or topical steroids 30 days before study, nasal decongestant, antihistamines, sodium cromolyn, anticholinergics for 7 previous days, use of cardiovascular drugs, neuroleptics, hormones or any drug that causes allergic rhinitis Tobacco consumption
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The sino-nasal outcomes test-22 average score. Timepoint: Before intervention and 2 months after intervention. Method of measurement: The sino-nasal outcomes test-22 questionnaire.;Lund-Mackay average score. Timepoint: 2 months after intervention (one time). Method of measurement: Sinus CT scan. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAhmad Rezaeian
Esfahan University of Medical Sciences
Outcome results
None listed